NEW YORK, March 3, 2017 /PRNewswire/ --
Stock-Callers.com revisits the Medical Instruments and Supplies space which isengaged in the manufacture of a broad range of non-electromedical equipment. This diversity of product lines insulates companies, as well as the whole industry, from extreme volatility, as fluctuations in demand for any one specific product have only
Illinois headquartered Baxter International Inc.'s stock finished Thursday's session 0.86% lower at $50.77 with a total trading volume of 2.15 million shares. Over the last month and the previous three months, the Company's shares have advanced 6.24% and 14.05%, respectively. Additionally, the stock has gained 14.79% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 8.02% and 9.82%, respectively. Moreover, shares of Baxter International, which provides a portfolio of renal and hospital products, have a Relative Strength Index (RSI) of 75.49.
On February 28th, 2017, Baxter and ScinoPharm Taiwan, Ltd announced a strategic partnership to develop, manufacture, and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy. The arrangement also provides Baxter the option to partner with ScinoPharm on as many as 15 additional injectable molecules. Visit us today and download your complete report on BAX for free at: http://stock-callers.com/registration/?symbol=BAX
Shares in Pennsylvania headquartered DENTSPLY SIRONA Inc. declined 1.32%, ending yesterday's session at $63.65 with a total trading volume of 972,930 shares. The stock has gained 12.26% in the past month, 5.40% in the previous three months, and 10.25% on an YTD basis. The Company's shares are trading 8.34% above their 50-day moving average and 5.74% above their 200-day moving average. Moreover, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the US and internationally, have an RSI of 70.00.
On February 17th, 2017, DENTSPLY reported net sales of $996.5 million for Q4 2016, up 48.5% compared to $671.1 million in Q4 2015. The Company's US reported net sales of $329.0 million increased 48.2% for Q4 2016 compared to $222.0 million in Q4 2015. Net income attributable to DENTSPLY for Q4 2016 was $107.0 million, or $0.46 per diluted share, compared to $58.6 million, or $0.41 per diluted share, in Q4 2015.
On February 21st, 2017, research firm Barrington Research downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. The complimentary research report on XRAY can be accessed at: http://stock-callers.com/registration/?symbol=XRAY
On Thursday, Minnesota-based Skyline Medical Inc.'s stock saw a drop of 8.98%, to close the day at $2.33. A total volume of 1.31 million shares was traded, which was above their three months average volume of 767,770 shares. The Company's shares have advanced 3.56% in the last one month. The stock is trading 6.54% below its 50-day moving average. Additionally, shares of Skyline Medical, which manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the US, have an RSI of 53.57.
On March 01st, 2017, Skyline Medical announced that it has received an Innovative Technology contract from Vizient, Inc. With an annual purchasing volume of almost $100 billion, Vizient is the largest, member-driven health care performance improvement Company in the country. Register for free on Stock-Callers.com and download the PDF research report on SKLN at: http://stock-callers.com/registration/?symbol=SKLN
Shares in Illinois headquartered Hill-Rom Holdings Inc. ended the day 0.65% lower at $66.77 with a total trading volume of 289,037 shares. The stock has gained 13.42% in the last one month, 24.12% in the previous three months, and 18.93% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 11.31% and 19.11%, respectively. Furthermore, shares of Hill-Rom Holdings, which operates as a medical technology company worldwide, have an RSI of 76.04.
On February 08th, 2017, research firm Barclays initiated an 'Overweight' rating on the Company's stock, with a target price of $70 per share.
On February 14th, 2017, Hill-Rom Holdings announced that it has completed its acquisition of Mortara Instrument, Inc. for $330 million in cash, primarily financed through a private offering of $300 million of senior unsecured notes. Hill-Rom anticipates the structure of the acquisition will allow it to qualify for a significant tax benefit, which at a net present value of approximately $40 million reduces the effective purchase price to approximately $290 million. Get free access to your research report on HRC at: http://stock-callers.com/registration/?symbol=HRC
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All